tradingkey.logo

Novartis nears $70-plus per share deal to acquire Avidity Biosciences, Bloomberg News reports

ReutersOct 26, 2025 3:06 PM

- Swiss drugmaker Novartis AG NOVN.S is close to acquiring U.S. biotech Avidity Biosciences RNA.O for over $70 per share, Bloomberg News reported on Sunday, citing a person familiar with the matter.

Reuters could not immediately confirm the report.

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI